Fabry care is a two-front contest: enzyme replacement versus an oral chaperone that only ~35–50% of patients can take, while a second IV ERT, pegunigalsidase, challenges Fabrazyme's two-decade incumbency.
Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations and deficient alpha-galactosidase A activity, leading to globotriaosylceramide (GL-3) accumulation and progressive renal, cardiac, and cerebrovascular disease. The US treated population is served by three FDA-approved agents across two mechanisms. Two are intravenous enzyme replacement therapies (ERTs): agalsidase beta (Fabrazyme, Sanofi Genzyme), approved in 2003 and the long-standing formulary incumbent, and pegunigalsidase alfa (Elfabrio, Chiesi/Protalix), a PEGylated plant-cell-derived alpha-Gal A approved in May 2023. The third is migalastat (Galafold, Amicus Therapeutics), an oral pharmacological chaperone approved in 2018.
The commercial story turns on two contests. First, mechanism: migalastat offers oral, every-other-day dosing as an alternative to biweekly IV infusion — but only for patients whose GLA mutation is amenable to chaperoning, roughly 35–50% of the population, confirmed by a validated cell-based assay. The ATTRACT trial showed migalastat gave renal outcomes comparable to ERT in ERT-experienced patients; FACETS showed substrate reduction in treatment-naïve patients. Second, ERT-versus-ERT: pegunigalsidase's BALANCE trial demonstrated non-inferiority to agalsidase beta on eGFR slope over two years, giving payers and prescribers a second IV option against an incumbent that has carried a WAC near $250,000–$350,000 for two decades with no US biosimilar.
FDA-approved Fabry disease therapies — United States, 2026
| Drug (Brand / INN) | Mechanism | Company | Route & Eligibility | US Approval | Key Trial Result |
|---|---|---|---|---|---|
| Fabrazyme (agalsidase beta) | Alpha-galactosidase A enzyme replacement | Sanofi Genzyme | IV every 2 weeks; all GLA genotypes | Apr 2003 | Phase 3: GL-3 clearance from renal capillary endothelium 69% vs 0% placebo (per Drugs@FDA / PI) |
| Galafold (migalastat) | Oral pharmacological chaperone | Amicus Therapeutics | Oral every other day; amenable GLA mutations only (~35–50%) | Aug 2018 | ATTRACT: renal function comparable to ERT; LV mass index −6.6 g/m² over 18 months |
| Elfabrio (pegunigalsidase alfa) | PEGylated plant-cell alpha-Gal A enzyme replacement | Chiesi / Protalix | IV every 2 weeks; all GLA genotypes | May 2023 | BALANCE: non-inferior to agalsidase beta on 2-year eGFR slope (median difference −0.36 mL/min/1.73m²/yr) |
Sources: FDA Drugs@FDA (approval status and dates); ATTRACT, J Med Genet 2017 (PMID 27834756); FACETS, NEJM 2016 (PMID 27509102); BALANCE, J Med Genet 2024 (PMID 37940383). Fabrazyme WAC per SSR Health / CMS Part B.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • ERT vs oral-chaperone mechanism and the amenable-mutation split • Efficacy across ATTRACT, FACETS and BALANCE • IV biweekly infusion vs oral every-other-day dosing and monitoring burden • Where pegunigalsidase's non-inferiority resets the ERT contest
Delivers
- • BALANCE non-inferiority result and the clinical-differentiation argument • Switch dynamics from an entrenched two-decade incumbent • Payer rationale requirements for changing a stable ERT patient • Absence of a US biosimilar and its pricing implications
Delivers
- • Amenable-mutation fraction (~35–50%) and the cell-based assay gate • Oral-eligible vs ERT-only patient segmentation • Treatment-naïve (FACETS) vs ERT-switch (ATTRACT) positioning • Commercial sizing of the oral-addressable population
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- How three FDA-approved Fabry therapies split between two IV enzyme replacement therapies and one oral chaperone.
- Why only roughly 35-50% of Fabry patients carry a GLA mutation amenable to migalastat's chaperone mechanism.
- How Sanofi Genzyme's Fabrazyme (2003), Amicus's Galafold (2018), and Chiesi/Protalix's Elfabrio (May 2023) entered the US market.
- Why Elfabrio's PEGylated, plant-cell-derived alpha-Gal A distinguishes it structurally from Fabrazyme's enzyme replacement approach.
- How pegunigalsidase's BALANCE trial showed non-inferiority to agalsidase beta on 2-year eGFR slope.
- Why switching a stable patient off a 2-decade Fabrazyme incumbent requires strong payer and clinical rationale.
- How a validated cell-based assay determines which Fabry patients qualify for oral migalastat treatment.
- Why ATTRACT and FACETS show migalastat matching ERT in switched patients and reducing substrate in treatment-naive ones.
- How Fabrazyme's roughly $250,000-$350,000 annual WAC has held for two decades without a US biosimilar entrant.
- Why payers weigh Elfabrio's clinical non-inferiority against the switching costs of disrupting a stable ERT patient.
- Why the absence of a US Fabrazyme biosimilar after two decades leaves room open for new entrants.
- How any next-generation Fabry therapy must beat BALANCE's non-inferiority bar or migalastat's oral convenience to compete.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Fabry Disease Competitive Intelligence sources: FDA Drugs@FDA (approval status and dates), primary trial publications in the New England Journal of Medicine and the Journal of Medical Genetics (FACETS, ATTRACT, BALANCE), ClinicalTrials.gov registrations, and Fabrazyme WAC per SSR Health / CMS Part B data.
- Migalastat vs ERT switch results verified against ATTRACT, J Med Genet 2017 (PMID 27834756)
- Migalastat treatment-naïve efficacy verified against FACETS, NEJM 2016 (PMID 27509102)
- Pegunigalsidase non-inferiority verified against BALANCE, J Med Genet 2024 (PMID 37940383)
- Approval status and indications verified against FDA Drugs@FDA
Frequently asked questions
Commission this brief
AXLRx delivers US Fabry disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.